{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T03:35:54Z","timestamp":1764905754176,"version":"3.44.0"},"reference-count":24,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2017,11,28]]},"abstract":"<jats:p>Guillain-Barr\u00e9 syndrome is a life-threatening neurological disorder that presents with rapid ascending paralysis and areflexia. Guillain-Barr\u00e9 syndrome is traditionally associated with infections from a gastrointestinal or respiratory tract source. We report the case of a 71-year-old man with melanoma who was treated with ipilimumab as adjuvant immunotherapy and subsequently developed Guillain-Barr\u00e9 syndrome. The diagnosis was made clinically through physical exam findings. He was successfully treated with a combination of intravenous immunoglobulin therapy and corticosteroids.<\/jats:p>","DOI":"10.1136\/bcr-2017-221318","type":"journal-article","created":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T06:25:10Z","timestamp":1513146310000},"page":"bcr-2017-221318","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Rare side effect of adjuvant ipilimumab after surgical resection of melanoma: Guillain-Barr\u00e9 syndrome"],"prefix":"10.1136","volume":"2017","author":[{"given":"Rohini J","family":"Patel","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, The University of Arizona Cancer Center, Tucson, Arizona, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, The University of Arizona Cancer Center, Tucson, Arizona, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akshay","family":"Amaraneni","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, The University of Arizona Cancer Center, Tucson, Arizona, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simran K","family":"Sindhu","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, The University of Arizona Cancer Center, Tucson, Arizona, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,12,13]]},"reference":[{"key":"2025082803370594000_2017.dec12_1.bcr-2017-221318.1","unstructured":"Howlader N , Noone AM , Krapcho M et al eds, . SEER CancerStatistics Review, National Cancer Institute,1975-2014. Bethesda, MD: National Cancer Institute. based on November 2016 SEER data submission, posted to the SEER web site, April 2017. https:\/\/seer.cancer.gov\/csr\/1975_2014\/"},{"key":"2025082803370594000_2017.dec12_1.bcr-2017-221318.2","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.suc.2014.07.001","article-title":"Workup and staging of malignant melanoma","volume":"94","author":"Kauffmann","year":"2014","journal-title":"Surg Clin North Am"},{"key":"2025082803370594000_2017.dec12_1.bcr-2017-221318.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70122-1"},{"key":"2025082803370594000_2017.dec12_1.bcr-2017-221318.4","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"2025082803370594000_2017.dec12_1.bcr-2017-221318.5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1470-2045(17)30015-3","article-title":"Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial","volume":"18","author":"Coens","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025082803370594000_2017.dec12_1.bcr-2017-221318.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"2025082803370594000_2017.dec12_1.bcr-2017-221318.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6750"},{"key":"2025082803370594000_2017.dec12_1.bcr-2017-221318.8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr028"},{"key":"2025082803370594000_2017.dec12_1.bcr-2017-221318.9","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2012-000447"},{"key":"2025082803370594000_2017.dec12_1.bcr-2017-221318.10","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31827807dd"},{"key":"2025082803370594000_2017.dec12_1.bcr-2017-221318.11","first-page":"A6185","article-title":"An unusual cause of acute respiratory failure","volume":"189","author":"Mukherjee","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2025082803370594000_2017.dec12_1.bcr-2017-221318.12","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/CJI.0000000000000167","article-title":"Ipilimumab-induced Guillain-Barr\u00e9 syndrome presenting as dysautonomia: an unusual presentation of a rare complication of immunotherapy","volume":"40","author":"Kelly Wu","year":"2017","journal-title":"J Immunother"},{"key":"2025082803370594000_2017.dec12_1.bcr-2017-221318.13","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/WCO.0000000000000503","article-title":"Neurological toxicities associated with immune-checkpoint inhibitors","volume":"30","author":"Touat","year":"2017","journal-title":"Curr Opin Neurol"},{"key":"2025082803370594000_2017.dec12_1.bcr-2017-221318.14","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0487"},{"key":"2025082803370594000_2017.dec12_1.bcr-2017-221318.15","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/WCO.0000000000000391","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"29","author":"Hottinger","year":"2016","journal-title":"Curr Opin Neurol"},{"key":"2025082803370594000_2017.dec12_1.bcr-2017-221318.16","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0455-8"},{"key":"2025082803370594000_2017.dec12_1.bcr-2017-221318.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.12.002"},{"key":"2025082803370594000_2017.dec12_1.bcr-2017-221318.18","article-title":"Swan AV, and van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome","volume":"19","author":"Hughes","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2025082803370594000_2017.dec12_1.bcr-2017-221318.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.02.024"},{"key":"2025082803370594000_2017.dec12_1.bcr-2017-221318.20","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou001"},{"key":"2025082803370594000_2017.dec12_1.bcr-2017-221318.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2014.06.023"},{"key":"2025082803370594000_2017.dec12_1.bcr-2017-221318.22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PLoS One"},{"key":"2025082803370594000_2017.dec12_1.bcr-2017-221318.23","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt285"},{"key":"2025082803370594000_2017.dec12_1.bcr-2017-221318.24","article-title":"Swan AV, and van Doorn PA. Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome","volume":"9","author":"Hughes","year":"2014","journal-title":"Cochrane Databse Syst Rev"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2017-221318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T10:37:15Z","timestamp":1756377435000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2017-221318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,13]]},"references-count":24,"alternative-id":["10.1136\/bcr-2017-221318"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2017-221318","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2017,12,13]]}}}